Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note published on Monday morning. The brokerage issued a hold rating on the stock.

A number of other analysts also recently issued reports on the stock. Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. HC Wainwright cut their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Monday, August 12th. Brookline Capital Management reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Securities reaffirmed a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Oncternal Therapeutics has a consensus rating of “Hold” and an average price target of $20.00.

Oncternal Therapeutics Stock Up 1.6 %

NASDAQ ONCT opened at $1.29 on Monday. The company has a market capitalization of $3.82 million, a P/E ratio of -0.11 and a beta of 1.33. Oncternal Therapeutics has a 12-month low of $1.05 and a 12-month high of $13.14. The firm has a 50-day moving average price of $1.81 and a two-hundred day moving average price of $5.32.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. 16.05% of the stock is currently owned by institutional investors and hedge funds.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.